Search results for "propane"

showing 10 items of 486 documents

Enantio- and diastereocontrol in intermolecular cyclopropanation reaction of styrene catalyzed by dirhodium(II) complexes with bulky ortho-metalated …

2004

Enantiomerically pure dirhodium(II) complexes with ortho-metalated p-substituted aryl phosphines have been shown to be enantio- and diastereoselective in the cyclopropanation of styrene by ethyl diazoacetate. Enantioselectivities up to 91% and diastereoselectivities up to 90% are observed for ethyl cis-2-phenylcyclopropanecarboxylate. Estevan Estevan, Francisco, Francisco.Estevan@uv.es ; Lahuerta Peña, Pascual, Pascual.lahuerta@uv.es ; Lloret Fillol, Julio, Julio.Lloret@uv.es ; Sanau Torrecilla, Mercedes, Mercedes.Sanau@uv.es ; Ubeda Picot, M Angeles, Angeles.Ubeda@uv.es ; Vila Gomez, Jaume Llorenc, Jaume.Vila@uv.es

CyclopropanesModels MolecularReactionPhosphinesCyclopropanationUNESCO::QUÍMICAIntermolecularCrystallography X-RayMedicinal chemistryHydrocarbons Aromatic:QUÍMICA [UNESCO]CatalysisStyrenesCatalysisStyrenechemistry.chemical_compoundEthyl diazoacetateOrganometallic CompoundsMaterials ChemistryOrganic chemistryRhodiumIntermolecular ; Reaction ; Dirhodium ; Phosphines ; CyclopropanationMolecular StructureCyclopropanationArylIntermolecular forceUNESCO::QUÍMICA::Química analíticaMetals and AlloysStereoisomerismGeneral MedicineGeneral ChemistryDirhodiumSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialschemistryCyclization:QUÍMICA::Química analítica [UNESCO]Ceramics and Composites
researchProduct

Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells

2014

Abstract The anti-human immunodeficiency virus (HIV) drug efavirenz (EFV) alters mitochondrial function in cultured neurons and glial cells. Nitric oxide (NO) is a mediator of mitochondrial dysfunction associated with HIV central nervous system symptoms. We show that EFV promotes inducible nitric oxide synthase (iNOS) expression in cultured glial cells and generated NO undermines their mitochondrial function, as inhibition of NOS partially reverses this effect. EFV inhibits mitochondrial Complex I in both neurons and glia; however, when the latter cells are treated for longer periods, other mitochondrial complexes are also affected in accordance with the increased NO production. These findi…

CyclopropanesNNRTIEfavirenzAnti-HIV AgentsCentral nervous systemNitric Oxide Synthase Type IIMitochondrionBiologyNitric OxideNitric oxideCell Linechemistry.chemical_compoundMediatornitric oxidemedicineImmunology and AllergyHumansNeuronsNeurotoxicityelectron transport chainHIVefavirenzmedicine.diseasecentral nervous systemCell biologyBenzoxazinesMitochondriaNitric oxide synthasemitochondriaInfectious Diseasesmedicine.anatomical_structurechemistryAlkynesImmunologybiology.proteinNeurogliaNeuroglia
researchProduct

Cyclopropanation of Membrane Unsaturated Fatty Acids Is Not Essential to the Acid Stress Response of Lactococcus lactis subsp. cremoris

2011

ABSTRACT Cyclopropane fatty acids (CFAs) are synthetized in situ by the transfer of a methylene group from S -adenosyl- l -methionine to a double bond of unsaturated fatty acid chains of membrane phospholipids. This conversion, catalyzed by the Cfa synthase enzyme, occurs in many bacteria and is recognized to play a key role in the adaptation of bacteria in response to a drastic perturbation of the environment. The role of CFAs in the acid tolerance response was investigated in the lactic acid bacterium Lactococcus lactis MG1363. A mutant of the cfa gene was constructed by allelic exchange. The cfa gene encoding the Cfa synthase was cloned and introduced into the mutant to obtain the comple…

CyclopropanesPhysiologyMembrane lipidsMutantApplied Microbiology and BiotechnologyGas Chromatography-Mass SpectrometryMembrane LipidsStress PhysiologicalMembrane fluidityViability assayPhospholipidsUnsaturated fatty acidMicrobial ViabilityEcologybiologyLactococcus lactis subsp cremorisFatty AcidsGenetic Complementation TestLactococcus lactisMethyltransferasesbiology.organism_classificationLactococcus lactisBiochemistryFatty Acids UnsaturatedMutant ProteinsAcidsBacteriaFood ScienceBiotechnologyApplied and Environmental Microbiology
researchProduct

Inhalable Formulation Based on Lipid–Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast

2022

Here, novel lipid-polymer hybrid nanoparticles (LPHNPs), targeted to lung macrophages, were realized as potential carriers for Roflumilast administration in the management of chronic obstructive pulmonary disease (COPD). To achieve this, Roflumilast-loaded fluorescent polymeric nanoparticles, based on a polyaspartamide-polycaprolactone graft copolymer, and lipid vesicles, made from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-distearoyl-sn-glycero-phosphoethanolamine-N-(polyethylene glycol)-mannose, were properly combined using a two-step method, successfully obtaining Roflumilast-loaded hybrid fluorescent nanoparticles (Man-LPHFNPs@Roflumilast). These exhibit colloidal size and a ne…

CyclopropanesPolymers and PlasticsPolymersMacrophagesPhosphatidylethanolaminesAminopyridinesBioengineeringPolyethylene GlycolsBiomaterialsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBenzamidesMaterials ChemistryHumansNanoparticlesParticle SizeMannoseBiomacromolecules
researchProduct

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

2009

After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide. Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency. The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compound. The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500…

CyclopropanesPulmonary and Respiratory MedicinePhosphodiesterase Inhibitorsmedicine.drug_classDrug Evaluation PreclinicalAdministration OralAminopyridinesInflammationPharmacologyPulmonary Disease Chronic ObstructiveCOPD; Inflammation; Oral therapy; Phosphodiesterase 4; Preclinical pharmacology; RoflumilastBronchodilatormedicineAnimalsHumansCOPDPharmacology (medical)RoflumilastPhosphodiesterase 4InflammationCOPDLungOral therapybusiness.industryAnti-Inflammatory Agents Non-SteroidalBiochemistry (medical)medicine.diseasePulmonary hypertensionObstructive lung diseasemedicine.anatomical_structureTolerabilityBenzamidesImmunologyPhosphodiesterase 4 InhibitorsPreclinical pharmacologymedicine.symptombusinessRoflumilastmedicine.drug
researchProduct

Roflumilast for asthma: Weighing the evidence

2015

CyclopropanesPulmonary and Respiratory Medicinebusiness.industryAdrenal cortex hormonesBiochemistry (medical)AminopyridinesPharmacologyPlacebomedicine.diseaseAsthmaAdrenal Cortex HormonesAdministration InhalationBenzamidesHumansMedicinePharmacology (medical)Phosphodiesterase 4 InhibitorsbusinessRoflumilastAsthmamedicine.drugAminopyridinesPulmonary Pharmacology & Therapeutics
researchProduct

Anti-inflammatory medications for the treatment of pediatric obstructive sleep apnea

2020

CyclopropanesPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classAnti-Inflammatory AgentsAdministration OralAcetatesSulfidesAnti-inflammatorylaw.inventionRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansChildAdministration IntranasalMontelukastSleep Apnea Obstructivebusiness.industryInfantmedicine.diseaseObstructive sleep apneaTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthQuinolinesLeukotriene Antagonistsbusinessmedicine.drugPaediatric Respiratory Reviews
researchProduct

Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells.

2013

Respiratory syncytial virus (RSV) causes acute exacerbations in COPD and asthma. RSV infects bronchial epithelial cells (HBE) that trigger RSV associated lung pathology. This study explores whether the phosphodiesterase 4 (PDE4) inhibitor Roflumilast N-oxide (RNO), alters RSV infection of well-differentiated HBE (WD-HBE) in vitro. WD-HBE were RSV infected in the presence or absence of RNO (0.1-100 nM). Viral infection (staining of F and G proteins, nucleoprotein RNA level), mRNA of ICAM-1, ciliated cell markers (digital high speed videomicroscopy, β-tubulin immunofluorescence, Foxj1 and Dnai2 mRNA), Goblet cells (PAS), mRNA of MUC5AC and CLCA1, mRNA and protein level of IL-13, IL-6, IL-8, T…

CyclopropanesScienceAminopyridinesBronchiCell CountRespiratory Syncytial Virus InfectionsBiologyMucin 5ACImmunofluorescenceVirus ReplicationVirusAntioxidantsChloride ChannelsTubulinGene expressionmedicineHumansCiliaRNA MessengerRespiratory systemRoflumilastMessenger RNAMetaplasiaMultidisciplinarymedicine.diagnostic_testQRvirus diseasesCell DifferentiationEpithelial CellsForkhead Transcription FactorsAxonemal Dyneinsrespiratory systemViral LoadVirologyMolecular biologyRespiratory Syncytial VirusesOxidative StressViral replicationBenzamidesMedicineCytokinesTumor necrosis factor alphaGoblet CellsReactive Oxygen SpeciesBiomarkersmedicine.drugResearch ArticlePloS one
researchProduct

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir i…

2013

Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients. Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral therapy between 1 June 2004 and 15 April 2011 and who were followed up for at least 6 months. The primary endpoint was durability, define…

CyclopropanesTime FactorsPyridinesPyridineDrug ResistanceLopinavir/ritonavirLongitudinal StudieHIV InfectionsPharmacologyAntiviral therapyDeoxycytidineLopinavirCohort Studieschemistry.chemical_compoundimmune system diseasesRetrospective StudieOrganophosphonateMedicineEmtricitabineHIV InfectionPharmacology (medical)ViralLongitudinal StudiesProspective StudiesProspective cohort studyvirus diseasesLopinavirInfectious DiseasesAnti-Retroviral AgentsItalyAlkynesCombinationOligopeptideHIV/AIDSDrug Therapy CombinationOligopeptidesmedicine.drugHumanMicrobiology (medical)Benzoxazinemedicine.medical_specialtyEfavirenzTime Factorantiretroviral therapyAtazanavir SulfateOrganophosphonatesfirst-line therapy tenofovir emtricitabine atazanavir/ritonavirSettore MED/17 - MALATTIE INFETTIVEEmtricitabineDurabilityDrug TherapyInternal medicineDrug Resistance ViralDrug utilizationHumansAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Time Factors; Pharmacology; Pharmacology (medical); Infectious DiseasesTenofovirRetrospective StudiesAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time FactorsPharmacologyRitonavirbusiness.industryAdenineAtazanavirBenzoxazinesRegimenProspective StudiechemistryHIV-1RitonavirAnti-Retroviral AgentCohort StudieTenofovir/emtricitabinebusiness
researchProduct

Enhanced plasmonic processes in amino-rich plasma polymer films for applications at the biointerface

2021

A new plasmonic biosensor was developed in a planar chip-based format by coupling the plasmonic properties of gold nanoparticles (Au NPs) with the mechanical and bioadhesive features of unconventional organic thin films deposited from plasma, namely primary amine-based plasma polymer films (PPFs). A self-assembled layer of spherical Au NPs, 12 nm in diameter, was electrostatically immobilized onto optically transparent silanised glass. In the next step, the Au NP layer was coated with an 18 nm polymeric thick PPF layerviathe simultaneous polymerization/deposition of a cyclopropylamine (CPA) precursor performed by radio frequency discharge, both in pulsed and in continuous wave modes. The CP…

Cyclopropaneschemistry.chemical_classificationMaterials sciencePolymerstechnology industry and agricultureMetal NanoparticlesGeneral Physics and AstronomySerum Albumin HumanBiointerfaceBiosensing TechniquesPolymerContact angleBlood serumchemistryChemical engineeringColloidal goldHumansGoldPhysical and Theoretical ChemistryThin filmBiosensorSerum AlbuminPlasmonHumanSettore CHIM/02 - Chimica FisicaPhysical Chemistry Chemical Physics
researchProduct